A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 3,400 shares of BCYC stock, worth $77,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,400
Previous 6,400 46.88%
Holding current value
$77,214
Previous $159,000 57.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $2.46 Million - $3.03 Million
122,875 Added 206.72%
182,315 $3.69 Million
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $3.94 Million - $6.13 Million
-235,025 Reduced 79.81%
59,440 $1.48 Million
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $2.11 Million - $3.52 Million
158,768 Added 117.0%
294,465 $5.32 Million
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $488,365 - $644,201
24,541 Added 22.08%
135,697 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $832,966 - $1.26 Million
43,956 Added 65.41%
111,156 $2.84 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $684,884 - $1.07 Million
34,210 Added 103.7%
67,200 $1.43 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $313,983 - $507,120
-15,414 Reduced 31.84%
32,990 $976,000
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $3.41 Million - $5.54 Million
-194,930 Reduced 80.11%
48,404 $1.13 Million
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $2.4 Million - $8.7 Million
185,147 Added 318.19%
243,334 $4.08 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $1.37 Million - $2.01 Million
32,840 Added 129.56%
58,187 $3.54 Million
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $708,448 - $1.12 Million
25,347 New
25,347 $1.05 Million
Q1 2021

May 17, 2021

SELL
$19.12 - $30.25 $555,149 - $878,308
-29,035 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$17.95 - $21.36 $521,178 - $620,187
29,035 New
29,035 $521,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $674M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.